Direct administration of recombinant SFRP2 (He et al., 2010) or SFRP4 (Matsushima et al., 2010) into the heart post-MI reduced fibrosis and improved cardiac function in a dose-dependent manner, resulting in better infarct healing. Here, SFRP4 is linked to myocardial infarction.